Introduction {#section1-1534735420915275}
============

With the incidence of cancer increasing annually, this disease has become one of the most prominent health issues affecting humans worldwide. According to the World Health Organization,^[@bibr1-1534735420915275]^ approximately 780 000 new cases of liver cancer were reported worldwide in 2012. The incidence rate was 10.1 per 100 000 people, and the mortality rate was 5.1 per 100 000, the latter of which was ranked second among deaths caused by cancer. The incidence and mortality rates of liver cancer in Taiwan are higher than the global average; in 2011, the number of confirmed cases of liver cancer in Taiwan was approximately 11 292, and the incidence and mortality rates were 35.79 and 24.95 per 100 000 people, respectively. Liver cancer was ranked second among all deaths caused by cancer in Taiwan.^[@bibr2-1534735420915275]^ Currently, 3 methods are available for cancer treatment: Western medicine treatment, Chinese medicine treatment, and combined Chinese-Western medicine treatment (ie, adjunctive Chinese medicine treatment). Many cancer patients who receive Western medicine treatment also seek and use Chinese medicine treatment as adjunctive therapy. The use of Chinese medicine treatment in Taiwan has increased among patients with liver cancer, and the ratio of Chinese medicine treatment users remains high (18.89%).^[@bibr3-1534735420915275]^ A previous study showed that the use of Chinese medicine treatment by cancer patients significantly improved their overall quality of life and body functions.^[@bibr4-1534735420915275]^ In addition, the use of adjunctive Chinese medicine treatment significantly elevated the survival rate of lung cancer patients as well as their prognostic results.^[@bibr5-1534735420915275]^ The mortality rate from liver cancer is higher among men compared with their female counterparts,^[@bibr6-1534735420915275]^ and the risk increases with age.^[@bibr7-1534735420915275],[@bibr8-1534735420915275]^ Furthermore, low socioeconomic status or family income, severity of comorbidity, and liver cancer stage increase the risk of death.^[@bibr6-1534735420915275],[@bibr9-1534735420915275][@bibr10-1534735420915275][@bibr11-1534735420915275]-[@bibr12-1534735420915275]^ Other related factors influencing the survival rate of cancer patients include medical institution characteristics,^[@bibr13-1534735420915275],[@bibr14-1534735420915275]^ physician service volume, and physician age.^[@bibr14-1534735420915275],[@bibr15-1534735420915275]^

Previous studies^[@bibr5-1534735420915275],[@bibr16-1534735420915275]^ have shown that adjunctive Chinese medicine treatment can significantly improve the survival rates of patients with cancer (eg, breast cancer patients and lung cancer patients). However, few studies have investigated the difference in the survival rates of liver cancer patients between Western medicine treatment and adjunctive Chinese medicine treatment. Therefore, this study was conducted to investigate the effect of adjunctive Chinese medicine treatment on the survival rate of patients with liver cancer.

Materials and Methods {#section2-1534735420915275}
=====================

Research Database {#section3-1534735420915275}
-----------------

This retrospective cohort study examined the Taiwan Cancer Registry for the 2004 to 2010 period, the National Health Insurance Research Database (NHIRD) for the 2002 to 2012 period, and the Cause of Death Data for the 2004 to 2012 period. The cancer registry data were obtained from the Health Promotion Administration, and the other data were obtained from the Ministry of Health and Welfare. The Taiwan Cancer Registry contains information on numerous cancer cases as well as relevant information such as patients' cancer stage. Diagnosis of cancer is confirmed according to the *International Classification of Diseases for Oncology, 3rd edition* (ICD-O-3), which identifies cancer categories according to primary site, histology, behavioral code, and classification/differentiation. In determining the cancer stage according to diagnostic results, the Taiwan Cancer Registry assesses the severity of cancer clinically, surgically, and pathologically in accordance with the tumor-node-metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC).^[@bibr17-1534735420915275]^ The NHIRD contains comprehensive health care--related information such as the characteristics of Taiwan's health care providers and patients' demographic information and all medical records including Western medicine and Chinese medicine. As of 2013, 23 462 863 people were enrolled in the National Health Insurance (NHI) program, accounting for approximately 99.6% of people living in Taiwan.^[@bibr18-1534735420915275]^

Study Population {#section4-1534735420915275}
----------------

In this study, patients whose liver cancer (ICD-O-3 codes C22.0-C22.1) was newly diagnosed with a stage I, II, or III and also received a surgery treatment between 2004 and 2010 were selected as the study participants, and they were followed up until December 31, 2012. Patients were excluded if they had carcinoma in situ (n = 6541), did not receive any treatment within the past 6 months (n = 5446), received only palliative care (n = 48), died within 3 months of diagnosis (n = 12 557), received only Chinese medicine treatment (n = 1972), or did not receive liver surgery (n = 5451; [Figure 1](#fig1-1534735420915275){ref-type="fig"}). In the present study, the 2 treatments were defined according to Lee et al,^[@bibr16-1534735420915275]^ as follows:

1.  *Western medicine treatment*: patients who received Western medicine treatment within 1 year of diagnosis and \<30 days of Chinese medicine treatment.

2.  *Adjunctive Chinese medicine treatment*: patients who received Western medicine treatment and ≥30 days of Chinese medicine treatment within 1 year of diagnosis.

![Flowchart for the selection of study participants.](10.1177_1534735420915275-fig1){#fig1-1534735420915275}

All liver cancer patients were enrolled in the NHI program and had high accessibility to Western Medicine. All cancer patients were exempted from payments for cancer treatments under the NHI. Western Medicine was the primary treatment for all patients in our study. The exposure of Western Medicine was comparable in the 2 cohorts.

To facilitate a more accurate comparison of the survival rates between the patients who underwent Western medicine treatment and those who underwent adjunctive Chinese medicine treatment, this study adopted the propensity score matching (PSM) with the greedy matching by digit without replacement method to eliminate characteristic differences between the 2 groups with a ratio of 1:10.^[@bibr19-1534735420915275]^ It was the conditional probability of the patients receiving adjunctive Chinese medicine treatment, and its calculation was based on the variables that are given in [Table 1](#table1-1534735420915275){ref-type="table"}. Using the multivariate logistic regression model, the probability of the patients receiving adjunctive Chinese medicine treatment was estimated for matching between the 2 groups. The groups were matched by sex, age, monthly salary, urbanization level of residence location, other catastrophic illnesses or injuries, severity of comorbidity hepatitis B virus, hepatitis C virus, cirrhosis, cancer stage, and treatment methods.

###### 

Differences Between the Variables Prior to and After Propensity Score Matching for Patients Who Received Western Medicine Treatment and Those Who Received Adjunctive Chinese Medicine Treatment (2004-2010).

![](10.1177_1534735420915275-table1)

  Variables                                  Before Propensity Score Matching   After Propensity Score Matching                                                                                             
  ------------------------------------------ ---------------------------------- --------------------------------- -------- ------- ------ ------ -------- -------- -------- -------- ------- ------ ------- -------
  Total number                               23 581                             100.00                            22 209   94.18   1372   5.82            14 729   100.00   13 390   90.91   1339   9.09    
  Gender                                                                                                                                         .068                                                       .998
   Male                                      16 709                             70.86                             15 707   94.00   1002   6.00            10 675   72.48    9704     90.90   971    9.10    
   Female                                    6872                               29.14                             6502     94.62   370    5.38            4054     27.52    3686     90.92   368    9.08    
  Age                                                                                                                                            \<.001                                                     .321
   ≤40                                       1052                               4.46                              969      92.11   83     7.89            784      5.32     709      90.43   75     9.57    
   41-50                                     2791                               11.84                             2590     92.80   201    7.20            1948     13.23    1755     90.09   193    9.91    
   51-60                                     5807                               24.63                             5415     93.25   392    6.75            4009     27.22    3634     90.65   375    9.35    
   ≥61                                       13 931                             59.08                             13 235   95.00   696    5.00            7988     54.23    7292     91.29   696    8.71    
  Monthly salary (NTD)                                                                                                                           \<.001                                                     .901
   Low-income household                      186                                0.79                              178      95.70   8      4.30            85       0.58     77       90.59   8      9.41    
   ≤17 280                                   1059                               4.49                              996      94.05   63     5.95            644      4.37     581      90.22   63     9.78    
   17 280-22 800                             13 259                             56.23                             12 573   94.83   686    5.17            7797     52.94    7111     91.20   686    8.80    
   22 801-28,800                             3308                               14.03                             3130     94.62   178    5.38            1999     13.57    1821     91.10   178    8.90    
   28 801-36 300                             1580                               6.70                              1469     92.97   111    7.03            1126     7.64     1017     90.32   109    9.68    
   36 301-45 800                             2002                               8.49                              1857     92.76   145    7.24            1442     9.79     1307     90.64   135    9.36    
   45 801-57 800                             854                                3.62                              792      92.74   62     7.26            604      4.10     545      90.23   59     9.77    
   ≥57 801                                   1333                               5.65                              1214     91.07   119    8.93            1032     7.01     931      90.21   101    9.79    
  Urbanization level of residence location                                                                                                       .004                                                       .999
   Level 1                                   5901                               25.02                             5532     93.75   369    6.25            3898     26.46    3539     90.79   359    9.21    
   Level 2                                   6807                               28.87                             6396     93.96   411    6.04            4393     29.83    3995     90.94   398    9.06    
   Level 3                                   3431                               14.55                             3225     94.00   206    6.00            2151     14.60    1953     90.79   198    9.21    
   Level 4                                   4010                               17.01                             3796     94.66   214    5.34            2405     16.33    2193     91.19   212    8.81    
   Level 5                                   966                                4.10                              933      96.58   33     3.42            371      2.52     338      91.11   33     8.89    
   Level 6                                   1364                               5.78                              1275     93.48   89     6.52            954      6.48     865      90.67   89     9.33    
   Level 7                                   1102                               4.67                              1052     95.46   50     4.54            557      3.78     507      91.02   50     8.98    
  Other catastrophic illnesses or injuries                                                                                                       \<.001                                                     1.000
   No                                        21 317                             90.40                             20 024   93.93   1293   6.07            13 855   94.07    12 595   90.91   1260   9.09    
   Yes                                       2264                               9.60                              2185     96.51   79     3.49            874      5.93     795      90.96   79     9.04    
  Charlson Comorbidity Index                                                                                                                     .010                                                       .961
   ≤3                                        20 250                             85.87                             19 034   94.00   1216   6.00            13 050   88.60    11 866   90.93   1184   9.07    
   4-6                                       2634                               11.17                             2513     95.41   121    4.59            1290     8.76     1170     90.70   120    9.30    
   ≥7                                        697                                2.96                              662      94.98   35     5.02            389      2.64     354      91.00   35     9.00    
  Hepatitis B virus                                                                                                                              \<.001                                                     .792
   No                                        12 992                             55.10                             12 310   94.75   682    5.25            7525     51.09    6846     90.98   679    9.02    
   Yes                                       10 589                             44.90                             9899     93.48   690    6.52            7204     48.91    6544     90.84   660    9.16    
  Hepatitis C virus                                                                                                                              .012                                                       .660
   No                                        14 448                             61.27                             13 563   93.87   885    6.13            9296     63.11    8443     90.82   853    9.18    
   Yes                                       9133                               38.73                             8646     94.67   487    5.33            5433     36.89    4947     91.05   486    8.95    
  Cirrhosis                                                                                                                                      \<.001                                                     .317
   No                                        6272                               26.60                             5851     93.29   421    6.71            4199     28.51    3801     90.52   398    9.48    
   Yes                                       17 309                             73.40                             16 358   94.51   951    5.49            10 530   71.49    9589     91.06   941    8.94    
  Cancer stage                                                                                                                                   \<.001                                                     .424
   Stage I                                   9527                               40.40                             8899     93.41   628    6.59            6350     43.11    5751     90.57   599    9.43    
   Stage II                                  6384                               27.07                             6028     94.42   356    5.58            3931     26.69    3579     91.05   352    8.95    
   Stage III                                 7670                               32.53                             7282     94.94   388    5.06            4448     30.20    4060     91.28   388    8.72    
  Treatment methods                                                                                                                              \<.001                                                     .330
   OP + CH + TACE                            5517                               23.40                             5268     95.49   249    4.51            3032     20.59    2783     91.79   249    8.21    
   OP                                        4723                               20.03                             4296     90.96   427    9.04            3921     26.62    3527     89.95   394    10.05   
   OP + CH + RT + TACE                       2787                               11.82                             2619     93.97   168    6.03            1926     13.08    1758     91.28   168    8.72    
   OP + RT                                   2531                               10.73                             2408     95.14   123    4.86            1413     9.59     1290     91.30   123    8.70    
   OP + TACE                                 2318                               9.83                              2215     95.56   103    4.44            1164     7.90     1061     91.15   103    8.85    
   OP + CH                                   1665                               7.06                              1553     93.27   112    6.73            1120     7.60     1008     90.00   112    10.00   
   OP + RFA                                  1730                               7.34                              1660     95.95   70     4.05            799      5.42     729      91.24   70     8.76    
   OP + CH + RT                              1300                               5.51                              1228     94.46   72     5.54            814      5.53     742      91.15   72     8.85    

Abbreviations: NTD, New Taiwan dollar; OP, surgery; CH, chemotherapy; TACE, embolization; RT, radiography; RFA, radiofrequency ablation.

Statistical Analysis {#section5-1534735420915275}
--------------------

The data were processed and analyzed using SAS Version 9.4. Descriptive and inferential statistical analyses were conducted with the level of significance set at α = .05.

Cancer stage was defined according to the TNM staging system of the AJCC (ie, stages I-III).^[@bibr20-1534735420915275]^ Area of residence was divided into 7 categories according to the degree of urbanization, with a value of 1 indicating the highest degree of urbanization. To evaluate the severity of comorbidities, primary and secondary diagnosis codes from the International Classification of Diseases, Ninth Revision, Clinical Modification, were converted into weighted scores. The weighted scores were subsequently summed to obtain the Charlson Comorbidity Index (CCI),^[@bibr21-1534735420915275]^ which was then applied to calculate the comorbidity scores. These scores, which represented the severity of the comorbidities, were divided into 3 levels (≤3, 4-6, and ≥7). Patients were considered to have other catastrophic illnesses or injuries only if other catastrophic illnesses or injuries had been diagnosed prior to their liver cancer diagnosis. Primary medical institution was determined according to the type of health care facility that the patients frequented the most for treatment during the observation period. The service volume of hospitals or physicians was defined as the number of liver cancer patients who were treated in a given year by the hospital or physician. The service volume of hospitals or physicians was divided into 3 levels by interquartile range: low (≤25%), median (25% to 75%), and high (≥75%).

After the study population was divided into Western and adjunctive Chinese medicine treatment groups, the χ^2^ test was applied to identify any differences in the demographic information, liver cancer stage, and health status of the 2 groups before and after conducting the PSM with a 1:10 matching ratio by using greedy matching by digit without replacement. Cox proportional hazards models were employed to examine related factors influencing the survival rate of the patients with liver cancer, and the patients' survival period was measured in years. The independent variables in the analysis were cancer treatment method, demographic characteristics, liver cancer stage, health status, physician characteristics, and characteristics of primary medical institution. The dependent variable was whether the patients survived. Last, patient survival was analyzed and calculated using the Kaplan-Meier method according to 1-, 3-, and 5-year survival rates. The results were employed to plot the survival curves for both of the treatment methods (for all patients and stratified by cancer stage). The log-rank test was then used to test the differences in the patient survival rates. This study has been approved by the research ethics committee in China Medical University (Institutional Review Board No. CMU-REC-101-012).

Results {#section6-1534735420915275}
=======

Characteristics of Liver Cancer Patients Prior to and After PSM {#section7-1534735420915275}
---------------------------------------------------------------

[Table 1](#table1-1534735420915275){ref-type="table"} shows that prior to PSM, the sex, age, monthly salary, urbanization level of residence location, other catastrophic illnesses or injuries, severity of comorbidity, whether or not the liver cancer patients had hepatitis B virus, whether or not the liver cancer patients had hepatitis C virus, whether or not the liver cancer patients had cirrhosis, cancer stage, and treatment methods of liver cancer patients who underwent Western medicine treatment differed significantly from those who underwent adjunctive Chinese medicine treatment (*P* \< .05). PSM was subsequently employed, and liver cancer patients who received adjunctive Chinese medicine treatment (n = 1339) were matched with those who received Western medicine treatment (n = 13 390). The patients who underwent adjunctive Chinese medicine treatment were mostly men (9.10%). The largest groups of patients who had received adjunctive Chinese medicine treatment were patients ≥61 years of age (8.71%), monthly salary in 17 280 to 22 800 NTD (New Taiwan dollar; 8.80%), urbanization level of residence location with level 2 (9.06%), without other catastrophic illnesses or injuries (9.09%), a low severity of comorbidities (9.07%), without hepatitis B virus (9.02%), without hepatitis C virus (9.18%), with cirrhosis (8.94%), stage I liver cancer patients (9.43%), and those who received the treatment method of only operation (10.05%). Among the patients who underwent adjunctive Chinese medicine treatment, the mean, median, minimum, and maximum number of days of treatment in the first year after diagnosis was 110, 84, 30, and 365 days, respectively. Subsequently, the χ^2^ test was employed to analyze whether the characteristics of the liver cancer patients who received Western medicine treatment differed from those who received adjunctive Chinese medicine treatment. The results show that according to the sex, age, monthly salary, urbanization level of residence location, other catastrophic illnesses or injuries, severity of comorbidity, whether or not the liver cancer patients had hepatitis B virus, whether or not the liver cancer patients had hepatitis C virus, whether or not the liver cancer patients had cirrhosis, cancer stage, and treatment methods, the differences between the 2 groups were nonsignificant (*P* \> .05).

The Effect of Adjunctive Chinese Medicine Treatment on the Survival Rate of Liver Cancer Patients and Related Factors {#section8-1534735420915275}
---------------------------------------------------------------------------------------------------------------------

After performing the PSM for the patients who received adjunctive Chinese medicine treatment and those who received Western medicine treatment, Cox proportional hazards models were employed to conduct an analysis, the results of which showed that the liver cancer patients who received adjunctive Chinese medicine treatment exhibited a hazard ratio (HR) of 0.68 compared with those who received Western medicine treatment (95% confidence interval \[CI\] = 0.62-0.74; [Table 2](#table2-1534735420915275){ref-type="table"}). Subsequently, all of the related variables were controlled, and the survival curves for both patient groups were plotted ([Figure 2](#fig2-1534735420915275){ref-type="fig"}). The curves show that compared with those who received Western medicine treatment, the patients who received adjunctive Chinese medicine treatment exhibited higher 1-year (83% vs 72%), 3-year (53% vs 44%), and 5-year (40% vs 31%) survival rates.

###### 

Effect of Adjunctive Chinese Medicine Treatment on the Survival Rate of Liver Cancer Patients and Related Factors.

![](10.1177_1534735420915275-table2)

  Variables                                  Survival        Death           *P*      Adjusted HR   95% CI   *P*                
  ------------------------------------------ --------------- --------------- -------- ------------- -------- ------ ----------- --------
  Total number                               4930            33.47           9799     66.53                                     
  Treatment                                                                                         \<.001                      
   Western medicine *(ref)*                  4403            32.88           8987     67.12                                     
   Adjunctive Chinese medicine               527             39.36           812      60.64                  0.68   0.62-0.74   \<.001
  Gender                                                                                            \<.001                      
   Male *(ref)*                              3523            33.00           7152     67.00                                     
   Female                                    1407            34.71           2647     65.29                  1.00   0.96-1.05   .937
  Age                                                                                               \<.001                      
   ≤40 *(ref)*                               287             36.61           497      63.39                                     
   41-50                                     655             33.62           1293     66.38                  1.08   0.97-1.20   .142
   51-60                                     1481            36.94           2528     63.06                  1.09   0.98-1.20   .102
   ≥61                                       2507            31.38           5481     68.62                  1.25   1.13-1.37   \<.001
  Average age (mean ± SD)                    60.51 ± 12.14   62.32 ± 12.79   \<.001                                             
  Monthly salary (NTD)                                                                              \<.001                      
   Low-income household *(ref)*              30              35.29           55       64.71                                     
   ≤17 280                                   208             32.30           436      67.70                  0.94   0.71-1.25   .677
   17 280-22 800                             2311            29.64           5486     70.36                  0.96   0.73-1.25   .754
   22 801-28 800                             735             36.77           1264     63.23                  0.91   0.69-1.19   .475
   28 801-36 300                             426             37.83           700      62.17                  0.87   0.66-1.14   .301
   36 301-45 800                             560             38.83           882      61.17                  0.82   0.63-1.08   .161
   45 801-57 800                             237             39.24           367      60.76                  0.83   0.62-1.10   .188
   ≥57 801                                   423             40.99           609      59.01                  0.75   0.57-0.99   .045
  Urbanization level of residence location                                                          \<.001                      
   Level 1 *(ref)*                           1406            36.07           2492     63.93                                     
   Level 2                                   1548            35.24           2845     64.76                  0.97   0.92-1.03   .287
   Level 3                                   669             31.10           1482     68.90                  1.11   1.04-1.19   .001
   Level 4                                   751             31.23           1654     68.77                  1.01   0.94-1.07   .870
   Level 5                                   120             32.35           251      67.65                  1.02   0.89-1.16   .801
   Level 6                                   257             26.94           697      73.06                  1.12   1.03-1.22   .012
   Level 7                                   179             32.14           378      67.86                  1.02   0.92-1.14   .685
  Other catastrophic illnesses or injuries                                                          \<.001                      
   No *(ref)*                                4693            33.87           9162     66.13                                     
   Yes                                       237             27.12           637      72.88                  1.30   1.20-1.41   \<.001
  Charlson Comorbidity Index                                                                        \<.001                      
   ≤3 *(ref)*                                4476            34.30           8574     65.70                                     
   4-6                                       362             28.06           928      71.94                  1.16   1.08-1.24   \<.001
   ≥7                                        92              23.65           297      76.35                  1.28   1.14-1.44   \<.001
  Hepatitis B virus                                                                                 .086                        
   No *(ref)*                                2500            33.22           5025     66.78                                     
   Yes                                       2430            33.73           4774     66.27                  0.95   0.91-1.00   .033
  Hepatitis C virus                                                                                 \<.001                      
   No *(ref)*                                3106            33.41           6190     66.59                                     
   Yes                                       1824            33.57           3609     66.43                  0.89   0.85-0.94   \<.001
  Cirrhosis                                                                                         \<.001                      
   No *(ref)*                                1901            45.27           2298     54.73                                     
   Yes                                       3029            28.77           7501     71.23                  1.56   1.48-1.63   \<.001
  Cancer stage                                                                                      \<.001                      
   Stage I *(ref)*                           3136            49.39           3214     50.61                                     
   Stage II                                  1292            32.87           2639     67.13                  1.40   1.32-1.47   \<.001
   Stage III                                 502             11.29           3946     88.71                  3.42   3.25-3.59   \<.001
  Treatment methods                                                                                 \<.001                      
   OP + CH + TACE *(ref)*                    886             29.22           2146     70.78                                     
   OP                                        1809            46.14           2112     53.86                  0.90   0.84-0.96   .001
   OP + CH + RT + TACE                       341             17.71           1585     82.29                  1.30   1.22-1.39   \<.001
   OP + RT                                   549             38.85           864      61.15                  1.08   0.99-1.17   .082
   OP + TACE                                 339             29.12           825      70.88                  0.94   0.86-1.02   .109
   OP + CH                                   289             25.80           831      74.20                  1.33   1.23-1.45   \<.001
   OP + RFA                                  479             59.95           320      40.05                  0.61   0.54-0.69   \<.001
   OP + CH + RT                              105             12.90           709      87.10                  1.83   1.68-2.00   \<.001
   OP + CH + TACE                            133             24.63           407      75.37                  1.11   1.00-1.23   .061
  Level of hospital                                                                                 \<.001                      
   Medical center *(ref)*                    3289            34.70           6190     65.30                                     
   Regional hospital                         1091            31.05           2423     68.95                  1.13   1.07-1.19   \<.001
   District hospital                         368             29.39           884      70.61                  1.18   1.10-1.28   \<.001
   Physician Clinics                         182             37.60           302      62.40                  1.17   0.99-1.38   .074
  Ownership of hospital                                                                             \<.001                      
   Public *(ref)*                            1712            35.58           3100     64.42                                     
   Nonpublic                                 3218            32.45           6699     67.55                  1.00   0.96-1.05   .856
  Service volume of hospitals                                                                       .185                        
   Low *(ref)*                               28              31.82           60       68.18                                     
   Median                                    63              37.50           105      62.50                  1.09   0.78-1.52   .624
   High                                      4839            33.43           9634     66.57                  1.11   0.83-1.48   .490
  Service volume of physician                                                                       .185                        
   Low *(ref)*                               62              24.51           191      75.49                                     
   Median                                    162             28.98           397      71.02                  0.87   0.73-1.04   .135
   High                                      4706            33.81           9211     66.19                  0.70   0.59-0.81   \<.001
  Age of physician                                                                                  \<.001                      
   ≤40 *(ref)*                               1365            28.86           3365     71.14                                     
   41-50                                     2278            34.56           4313     65.44                  0.90   0.86-0.95   \<.001
   51-60                                     1120            36.95           1911     63.05                  0.83   0.78-0.88   \<.001
   ≥61                                       167             44.30           210      55.70                  0.82   0.71-0.94   .005

Abbreviations: HR, hazard ratio; CI, confidence interval; NTD, New Taiwan dollar; OP, surgery; CH, chemotherapy; TACE, embolization; RT, radiography; RFA, radiofrequency ablation.

![Survival curves of liver cancer patients were performed by the Cox proportional hazard model, in which 1 group received Western medicine treatment (n~1~ = 13 390) and another group received adjunctive Chinese medicine treatment (n~2~ = 1339).](10.1177_1534735420915275-fig2){#fig2-1534735420915275}

When stratified by cancer stage ([Figure 3](#fig3-1534735420915275){ref-type="fig"}), significant differences were observed between the 2 groups (*P* \< .05). The 5-year survival rate of patients with stage I liver cancer who received adjunctive Chinese medicine treatment (56%) was higher than that of those who received Western medicine treatment (48%). Similarly, the 5-year survival rate of the patients with stage II liver cancer patients who received adjunctive Chinese medicine treatment (41%) was higher than that of those who received Western medicine treatment (30%).

![Survival curves of liver cancer patients performed by the Cox proportional hazard model are displayed by cancer stage, in which one group received Western medicine treatment (n~1~ = 13 390) and another group received adjunctive Chinese medicine treatment (n~2~ = 1339).](10.1177_1534735420915275-fig3){#fig3-1534735420915275}

Related Factors Influencing Liver Cancer Patients Survival {#section9-1534735420915275}
----------------------------------------------------------

[Table 2](#table2-1534735420915275){ref-type="table"} shows that the risk of death was equal between women and men (HR = 1.00; 95% CI = 0.96-1.05). Furthermore, the risk increased with age: liver cancer patients ≥61 years exhibited a significantly higher risk of death compared with those aged ≤40 years (HR = 1.25; 95% CI = 1.13-1.37). The risk of death of the patients with the highest monthly salaries was 0.75 times that of low-income earners (95% CI = 0.57-0.99). Regarding urbanization level of residence location, the risk of death of the patients who lived in the areas with lowest degree of urbanization was 1.02 times that of those living in the areas with the highest degree of urbanization (95% CI = 0.92-1.14). The patients with other catastrophic illnesses or injuries exhibited a risk of death that was significantly higher than those without other catastrophic illnesses or injuries (HR = 1.30; 95% CI = 1.20-1.41). Regarding the health status of the liver cancer patients, the more severe their comorbidities were, the higher the risk of death became; those with a CCI of ≥7 exhibited 1.28 times risk of death compared with those with a CCI of ≤3 (95% CI = 1.14-1.44). Moreover, the risk of death of the liver cancer patients with hepatitis C virus did not increase compared with those without hepatitis C virus (HR = 0.89; 95% CI = 0.85-0.94), but the risk of death of patients with cirrhosis was significantly higher than those without cirrhosis (HR = 1.56; 95% CI = 1.48-1.63). And the risk also increased with cancer stage, with that of stage III liver cancer patients (HR = 3.42; 95% CI = 3.25-3.59) significantly exceeding that of the stage I liver cancer patients. Regarding the primary medical institution characteristics, the lower the level of the medical institution was, the greater the risk of death became; the risk of death among the patients who received treatment at district hospitals were significantly higher than that of those who were treated at medical centers (HR = 1.18; 95% CI = 1.10-1.28). Concerning the ownership of the medical institutions, the risk of death for patients who received treatment at private medical institutions was similar with those who were treated at public medical institutions (HR = 1.00; 95% CI = 0.96-1.05), and the risk of death for patients who received treatments at hospitals with a different service volume was not significantly different. Finally, regarding physician age, the patients who received treatment primarily from physicians aged ≥61 years exhibited the lowest risk of death (HR = 0.82; 95% CI = 0.71-0.94).

[Table 3](#table3-1534735420915275){ref-type="table"} shows that for the patients who received adjunctive Chinese medicine treatment, the most frequently used traditional Chinese medicine regimen comprised 6 single-herb medicine and 4 herbal formulas. For single-herb medicines, the most frequently used medicines were bai hua she she cao (24.9%), ban zhi lian (12.1%), dan shen (10.8%), yin chen hao (6.9%), bie jia (6.5%), and ye jiao teng (5.6%); for herbal formulas, the 4 most frequently used formulas were jia wei xiao yao san (11.3%), xiao chai hu tang (10.9%), xiang sha liu jun zi tang (8.3%), and yin chen wu ling san (6.2%).

###### 

Top 10 Traditional Chinese Medicine Used by Patients Who Received Adjunctive Chinese Medicine Treatment.

![](10.1177_1534735420915275-table3)

  Name of Traditional Chinese Medicine   Ingredient                                                                                                                                                                                \%
  -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------
  *Bai Hua She She Cao*                  *Hedyotis diffusa*                                                                                                                                                                        24.9
  *Ban Zhi Lian*                         *Scutellaria barbata*                                                                                                                                                                     12.1
  *Jia Wei Xiao Yao San*                 *Angelica sinensis, Poria, Gardenia jasminoides, Menthae, Paeonia lactiflora, Bupleurum chinense* DC, *Glycyrrhiza uralensis, Atractylodes macrocephala, Moutan Radicis Cortex, Ginger*   11.3
  *Xiao Chai Hu Tang*                    *Bupleurum chinense* DC, *Scutellaria baicalensis* Georgi, *Talinum, Glycyrrhiza uralensis, Pinellia ternata, Ginger, Ziziphus jujuba*                                                    10.9
  *Dan Shen*                             *Salvia miltiorrhiza* Bge                                                                                                                                                                 10.8
  *Xiang Sha Liu Jun Zi Tang*            *Rosa banksiae, Fructus amomi, Pericarpium Citri Reticulatae, Pinellia ternata, Codonopsis pilosula, Poria, Glycyrrhiza uralensis, Ginger, Ziziphus jujuba*                               8.3
  *Yin Chen Hao*                         *Artemisia capillaris*                                                                                                                                                                    6.9
  *Bie Jia*                              *Carapax trionycis*                                                                                                                                                                       6.5
  *Yin Chen Wu Ling San*                 *Artemisia capillaris, Alisma plantago-aquatica, Atractylodes macrocephala, Poria, Polyporus umbellatus, Ramulus cinnamomi*                                                               6.2
  *Ye Jiao Teng*                         *Polygonum multiflorum* Thunb                                                                                                                                                             5.6

Discussion {#section10-1534735420915275}
==========

In this study, PSM was adopted to reduce selection bias, the results of which show that when all other related factors were controlled, the risk of death for the patients who received adjunctive Chinese medicine treatment was significantly lower than that of those who received Western medicine treatment (HR = 0.68). This indicates that adjunctive Chinese medicine treatment can improve the survival rate of patients with liver cancer, which supports the findings of previous studies investigating the effectiveness of adjunctive Chinese medicine treatment on improving the survival rate of patients with different types of cancer (ie, liver, lung, breast, and head and neck cancer)^[@bibr5-1534735420915275],[@bibr16-1534735420915275],[@bibr22-1534735420915275][@bibr23-1534735420915275]-[@bibr24-1534735420915275]^; however, in these studies, the patients were not stratified according to their cancer stage. Some studies have shown that combining Chinese medicine treatment with chemotherapy can significantly extend the survival period of patients with late-stage lung or colon cancer.^[@bibr25-1534735420915275],[@bibr26-1534735420915275]^ Meta-analyses have confirmed that compared with Western medicine treatment, adjunctive Chinese medicine treatment is more effective in elevating the survival period of patients with mid- to late-stage liver or lung cancer.^[@bibr27-1534735420915275],[@bibr28-1534735420915275]^ Cancer patients who received adjunctive Chinese medicine treatment exhibited increased suppression of cancer cells, which lowers the risk of death. In addition, Chinese medicine treatment eases the adverse reactions that patients experience during chemotherapy and radiation therapy.^[@bibr5-1534735420915275],[@bibr26-1534735420915275]^ Therefore, when patients with cancer elect to receive adjunctive Chinese medicine treatment, their clinical symptoms and quality of life can be improved and their survival can be extended.^[@bibr24-1534735420915275],[@bibr26-1534735420915275]^ The 10 traditional Chinese medicines used by the liver cancer patients who received adjunctive Chinese medicine treatment in the present study are similar to those reported in previous studies, indicating that the most common traditional Chinese medicines used by patients with liver cancer are jia wei xiao yao san, xiao chai hu tang, and xiang sha liu jun zi tang.^[@bibr29-1534735420915275]^ Other studies have indicated that jia wei xiao yao san, bai hua she she cao, ban zhi lian, and dan shen are traditional Chinese medicines that are commonly used to treat breast cancer.^[@bibr16-1534735420915275]^ Because no study has explored the effectiveness of adjunctive Chinese medicine for treating stage I to III liver cancer,^[@bibr29-1534735420915275],[@bibr30-1534735420915275]^ this study addressed this research gap and found that adjunctive Chinese medicine treatment exhibited more favorable treatment results on stage I and II liver cancer than on stage III liver cancer. This may be attributable to patients with stage I or II cancer having milder conditions that were easier to treat.

The results of this study support those reported by previous studies that have shown that the risk of death was lower for women than for men,^[@bibr6-1534735420915275],[@bibr7-1534735420915275],[@bibr31-1534735420915275],[@bibr32-1534735420915275]^ higher for older age groups and patients with a lower socioeconomic status,^[@bibr6-1534735420915275][@bibr7-1534735420915275]-[@bibr8-1534735420915275],10,11,[@bibr33-1534735420915275][@bibr34-1534735420915275]-[@bibr35-1534735420915275]^ higher with increasing severity of comorbidities,^[@bibr36-1534735420915275],[@bibr37-1534735420915275]^ and higher at later cancer stages.^[@bibr12-1534735420915275],[@bibr35-1534735420915275],[@bibr38-1534735420915275],[@bibr39-1534735420915275]^ In the present study, the risk of death increased with age; lower income; greater severity of comorbidities, catastrophic illnesses or injuries; and at later cancer stages. The results of previous studies have showed that the patients having hepatitis C virus may increase the risk of developing liver cancer.^[@bibr40-1534735420915275],[@bibr41-1534735420915275]^ This study adopted the PSM that included the variable of hepatitis C; since all patients have developed a liver cancer, the mortality risk of patients with liver cancer having hepatitis C was not significant.

For the patients who were treated at hospitals, the outcome of their treatment might have differed because of differences in the treatment provided by the hospitals due to different hospital characteristics. The results of this study were supported by previous studies and indicated that the postsurgery mortality rate of patients with a liver cancer is significantly lower in medical centers than nonmedical centers (including regional, district hospitals, and physician clinics).^[@bibr42-1534735420915275]^ Regarding ownership of hospitals, nonpublic hospitals (including private hospitals) showed a higher mortality rate than that of public hospitals,^[@bibr42-1534735420915275]^ but this study did not indicate the same outcome. The present study shows that the risk of death for patients with liver cancer increased significantly when treatment was received through lower level medical institutions, nonpublic institutions, and physicians with low service volumes, which accords with the results of previous studies.^[@bibr43-1534735420915275][@bibr44-1534735420915275]-[@bibr45-1534735420915275]^ Health behavior and lifestyle, which include smoking, drinking alcohol, exercise, and diet, may affect the survival of cancer patients. Previous studies have indicated that the risk of death was higher for cancer patients who have the habit of smoking and drinking alcohol.^[@bibr46-1534735420915275],[@bibr47-1534735420915275]^ In contrast, cancer patients who perform regular exercise and take a nutritional diet may have improved survival.^[@bibr48-1534735420915275],[@bibr49-1534735420915275]^ Although we could not include these health behaviors and lifestyle factors in the analysis model, we believe that these factors might have similar impacts on these 2 groups of patients.

Research Limitations {#section11-1534735420915275}
--------------------

This study was not a randomized clinical trial and used medical claim data compiled by the NHI Administration for analysis. The survival curves ([Figure 3](#fig3-1534735420915275){ref-type="fig"}) indicated that there was a significant association between the patients receiving adjunctive Chinese medicine treatment and the patients having better survival rate, but a cause and effect relationship could not be determined from these data. In addition, patients might have self-selected for medical treatment, leading to bias in the study. Although the NHI covers the most portion of the cost of both traditional Chinese and Western medical regimens, some patients may be required to pay for traditional Chinese medicines not covered by the NHI. Consequently, it remains unclear how such medical expenses incurred may have resulted in a possible underestimation of the number of patients who received adjunctive Chinese medicine treatment. In addition, the study was unable to determine whether the number of liver cancer patient deaths from the data reflects the actual number of deaths from liver cancer because the patients could have died from other causes. Finally, the external validity of this study results for other countries with different health care delivery systems is limited.

Conclusions {#section12-1534735420915275}
===========

After PSM was applied to reduce selection bias, the study results revealed that compared with those who received only Western medicine treatment, patients who received adjunctive Chinese medicine treatment exhibited a lower risk of death and increased survival rates. Related factors influencing the survival rate of liver cancer patients included demographic characteristics (ie, sex, age), income, area of residence, cancer stage, health status (ie, severity of comorbidities), catastrophic illness or injury status, cirrhosis, treatment methods, primary medical institution characteristics (ie, hospital level and ownership structure), and primary physician characteristics (ie, age). In addition, the effects of adjunctive Chinese medicine treatment on liver cancer patients differed among the patients according to cancer stage, in which the survival rate of the patients with stage I or II cancer was higher than that of patients with stage III or IV cancer.

According to the results of this study, we recommend that government or physicians should further conduct focused preclinical studies as well as well-designed and controlled prospective clinical trials. Future studies should consider investigating the underlying mechanisms of the medicines used in adjunctive Chinese medicine treatment to determine which type of traditional Chinese medicine or treatment is the most effective for improving the survival rate of patients with liver cancer.
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